脂联素与心血管疾病

脂联素是由脂肪组织分泌的一种细胞因子,与心血管疾病密切相关。脂联素通过抗炎和抗氧化抑制动脉粥样硬化发生。脂联素可促进血管生成,并具有保护心肌免受缺血再灌注损伤和减轻高压力负荷导致的心肌肥厚的功能。脂联素主要通过激活腺苷酸活化的蛋白激酶、环磷酸腺苷-蛋白激酶A等信号通路而发挥对心血管的保护作用。该文主要针对脂联素在心血管系统中的作用及其分子机制的研究进展作一综述。     

钙调神经磷酸酶信号通路相关抑制因子研究进展

钙调神经磷酸酶(calcineurin,CaN)信号通路是介导心肌肥厚的一条重要通路,随着研究的不断深入, 其相关抑制因子的研究也受到了更多关注.综述了Ca2+CaN-NFAT信号通路上、下游及CaN本身的部分抑制因子在抗心肌肥大过程中的作用,这些因子的研究开发对心肌肥厚的治疗具有重要意义.     

CyPA-CD147-ERK1/2-cyclinD2信号通路在大鼠左心室肥厚过程中表达上调(英文)

亲环素A(cyclophilin A,Cy PA),其受体CD147及其下游信号通路在心肌肥厚过程中变化情况不清楚。本实验目的是研究血清Cy PA、心肌中Cy PA、CD147及其信号通路与心肌肥厚的关系。大鼠左心室肥厚模型用2肾2夹(2-kidney,2-clip,2K2C)方法制备,并观察1周,4周和8周。用左心质量和体重比值(ratio of left ventricular heart weight to body weight,LVW/BW)及心肌横切面面积(cross sectional area,CSA)评价左心室肥厚。用ELISA检测血清中Cy PA水平。用蛋白免疫印迹和免疫组化观察Cy PA、CD147、磷酸化ERK1/2和cyclin D2在心肌组织中表达水平。在第4周和8周,与对照组比较,2K2C组大鼠血压明显增高,LVW/BW和CSA显著增加。ELISA结果显示2K2C组大鼠血清中Cy PA水平随着左心室肥厚程度加剧而明显增加。蛋白免疫印迹和免疫组化结果表明,Cy PA、CD147、磷酸化ERK1/2和cyclin D2在2K2C组大鼠心肌组织中表达水平也随左心室肥厚发展而增加。本研究表明血清中Cy PA水平以及心肌组织中Cy PA-CD147-ERK1/2-cyclin D2信号通路在心肌肥厚发展过程中被激活并表达上调,提示该信号通路在左心室肥厚发病机制中可能发挥了作用。     

Wnt/β-catenin信号通路及其在心脏疾病中的作用

Wnt/β-catenin信号通路是以调控β-catenin的稳定性和核定位为核心过程的经典Wnt通路,在细胞增殖、分化和组织稳态维持过程中发挥重要作用.许多细胞外基质蛋白、生长因子等参与该通路的上游调控,此外其他信号通路可以通过与其相互作用精确调控细胞生理功能.在心脏中该通路的异常激活是导致心肌肥厚和心肌损伤的病理生...     

心肌肥厚过程中PKC的双刃剑作用

在慢性压力超负荷致心肌肥厚过程中,蛋白激酶C(PKC)是促心肌细胞肥大信号转导通路上的关键分子。心肌中PKC存在多种异构体,其各自的功能与作用尚不清楚。借助于PKC的选择性激动剂与抑制剂、腺病毒转染或转基因模型的研究表明,不同种属心肌中共同拥有的PKC有四种,它们的作用分别为:PKCε、PKCβ与PKCδ均可独立介导心肌细胞肥大,相互间能发挥代偿作用;激活PKCα与PKCβ亦可导致心肌收缩性能降低,相反,激活PKCε可增强心肌收缩性能。PKC的这种既可促进心肌发生代偿性肥厚,又可降低心肌收缩性能而引起失代偿的双重作用,在肥厚心肌向心衰转化过程中值得关注。     

糖尿病心肌病相关信号通路的研究进展

糖尿病心肌病是一种独立、特异的心肌病,与糖尿病患者发生心力衰竭和死亡率升高密切相关。高血糖引起的心血管并发症涉及心肌病变和血管病变、心肌细胞结构的改变、信号通路和炎症因子的改变等,导致心肌纤维化、心肌肥厚、心脏肥大、心力衰竭和心律失常。综述了糖尿病心肌病发病机制中研究较多的几条信号通路,探究各信号通路在糖尿病心肌病发生、发展过程中对心脏的保护(损伤)作用的相关研究进展。     

中药抗心肌缺血再灌注损伤的信号通路研究进展

冠心病发生率、致死率高,严重危害人类健康。心肌缺血再灌注损伤是加重心肌损伤的主要病理机制,干预再灌注损伤挽救激酶、 单磷酸腺苷激酶、蛋白激酶 C 等信号传导通路保护心肌,成为减轻心肌损伤的重要途径之一。综述近 3 年国际期刊收录的中药有效成分、 提取物及复方制剂调节相关信号传导通路, 减轻心肌再灌注损伤的研究进展, 以期为阐释中药的作用特点, 有效防治心血管疾病提供参考。     

细胞核CaMK和Calcineurin 对大鼠心肌肥厚发生的作用

目的:研究大鼠心肌肥厚时,钙依赖的蛋白激酶和蛋白磷酸酶在心肌细胞膜、细胞浆和细胞核的分布规律,以探讨核钙信号与核反应在心肌肥厚发生过程中的病理生理意义.方法:制备腹主动脉缩窄大鼠心肌肥厚模型,同位素32P掺入法分别测定心肌细胞核、细胞浆和细胞膜的蛋白激酶活性及用无机磷生成显色法测定其蛋白磷酸酶活性.结果:腹主动脉缩窄术后4周大鼠心肌显著肥厚,伴有明显的血液动力学异常.与正常对照组相比较,腹主动脉缩窄心肌肥厚组心肌细胞核钙调素蛋白激酶(CaMK)活性增加101.1%(P＜0.01),其膜的酶活性升高40.2%(P＜0.01),而胞浆的酶活性不变(P＞0.05);心肌细胞核钙调神经磷酸酶(Calcineurin)活性增加43.6%(P＜0.05),膜和胞浆中其活性增加无显著性(P＞0.05).正常组和腹主动脉缩窄心肌肥厚组心肌细胞CaMK和Calcineurin活性分布为核＞膜＞胞浆(P＜0.01).结论:腹主动脉缩窄心肌肥厚时核内钙依赖的CaMK和Calcineurin活性增加,提示压力超负荷时细胞核内钙调节的蛋白磷酸化和去磷酸化水平增高,可能在介导心肌肥厚的发生中起重要作用.     

钙调神经磷酸酶依赖的信号通路在大鼠心肌肥大中的作用及调节

本工作在大体动物模型、细胞及分子水平上,对钙调神经磷酸酶（CaN)依赖的信号通路在大鼠豳肥大中的作用及其调节机制进行了研究。结果发现;（１）ＣaN信号通路参与血流动力学超负荷、心肌纤维化、旁／自分泌因子等诱导的心肌细胞肥大;（２）ＣaN信号通道参与血管紧张素Ⅱ(AngⅡ)及碱性成纤维细胞因子(bFGF)诱导的心肌细胞肥大和AngⅡ及bFGF刺激的心脏成纤维细胞增殖;（３）ＣaN通路与丝裂素活化蛋白激酶（ＭＡＰＫ）及蛋白激酶Ｃ（ＰＫＣ）信号途径可能存在相互关系;（４）ＣaN的活化依赖胞内Ｃa^2 浓度的持续升高,ＣaN的活化还受蛋白激酶磷酸化的调节,ＡngⅡ刺激心肌细胞ＣaNmRNA的表达显著增加,ＣaNmRNA本身的表达受Ｃa^2 信号及ＭＡＰＫ级联反应的调控。结论：Ｃa^2 -ＣaN信号通路介导心肌肥大的发生。     

miRNA在异丙肾上腺素诱导大鼠心肌肥厚中的表达及生物信息学分析*

目的:探讨miRNAs(miR199a-5P、miR206、miR133a-3P、miR499-5P)在异丙肾上腺素(ISO)诱导大鼠心肌肥厚模型组中的表达变化;并运用生物信息学方法分析相关的主要信号通路及分子机制。方法:将16只SD雄性大鼠随机分为2组:对照组和ISO模型组,模型组给予ISO(1 mg/kg)诱导心肌肥厚模型,对照组给予等量生理盐水,均采用背部皮下多点注射。连续给药10 d后采用超声心动图测量舒张期室间隔厚度(IVSd)、舒张期左室后壁厚度(LVPWd)、左室舒张末期内径(LVDd)及心脏收缩功能(EF%);称量心脏重量(HW)、大鼠体重(BW),并计算心脏/体重比(HW/BW);心肌组织HE染色,Image J分析软件测量心肌细胞表面积;RT-qPCR检测大鼠心肌组织中4种miRNAs的表达情况。运用Targetscan、miRDB、miRwalk 数据库预测大鼠4种miRNAs可能的靶基因,FunRich软件分析预测靶基因相关的信号通路。结果:与正常组相比,模型组IVSd、LVPWd增厚,LV增大,EF%明显降低;HW、HW/BW增加;模型组心肌细胞体积明显增大,排列紊乱,细胞表面积增加;模型组miR199a-5P、miR206表达上调(P＜0.05);miR133a-3P、miR499-5P表达下调(P＜0.05)。应用生物信息学预测4种miRNAs的靶基因可能参与心肌肥厚相关的信号通路主要有:VEGF/VEGFR信号通路、ErbB受体信号通路等。结论:ISO诱导心肌肥厚导致miRNAs表达的改变,生物信息学预测4种miRNAs参与心肌肥厚相关的靶基因及其主要信号通路,这些研究为心肌肥厚的调控机制及其防治措施提供了新思路。     

钙调神经磷酸酶依赖的信号通路参与血管紧张素Ⅱ刺激的心肌细胞肥大

本研究观察了钙调神经磷酸酶依赖的信号通路在血管紧张素Ⅱ诱导的大鼠心肌细胞肥大中的作用。在ＡｎｇⅡ刺激的大鼠心肌细胞肥大模型上,应用环孢素Ａ（ＣｓＡ）阻断ＣａＮ通路,观察心肌细胞＾３Ｈ－亮氨酸掺入,ＣａＮ,ＭＡＰＫ及ＰＫＣ活性的变化。结果表明,ＡｎｇⅡ（１０＾－７ｍｏｌ／Ｌ）刺激大鼠心肌细胞＾３Ｈ－亮氨酸掺入较对照组增高４６％（Ｐ〈０．０１）,ＣｓＡ（０．５－５μｇ／ｍｌ）可以浓度依赖性方式抑制Ａｎ     

Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) and Cyclic ADP-Ribose (cADPR) Mediate Ca2+ Signaling in Cardiac Hypertrophy Induced by β-Adrenergic Stimulation

Ca²⁺ signaling plays a fundamental role in cardiac hypertrophic remodeling, but the underlying mechanisms remain poorly understood. We investigated the role of Ca²⁺-mobilizing second messengers, NAADP and cADPR, in the cardiac hypertrophy induced by β-adrenergic stimulation by isoproterenol. Isoproterenol induced an initial Ca²⁺ transients followed by sustained Ca²⁺ rises. Inhibition of the cADPR pathway with 8-Br-cADPR abolished only the sustained Ca²⁺ increase, whereas inhibition of the NAADP pathway with bafilomycin-A1 abolished both rapid and sustained phases of the isoproterenol-mediated signal, indicating that the Ca²⁺ signal is mediated by a sequential action of NAADP and cADPR. The sequential production of NAADP and cADPR was confirmed biochemically. The isoproterenol-mediated Ca²⁺ increase and cADPR production, but not NAADP production, were markedly reduced in cardiomyocytes obtained from CD38 knockout mice. CD38 knockout mice were rescued from chronic isoproterenol infusion-induced myocardial hypertrophy, interstitial fibrosis, and decrease in fractional shortening and ejection fraction. Thus, our findings indicate that β-adrenergic stimulation contributes to the development of maladaptive cardiac hypertrophy via Ca²⁺ signaling mediated by NAADP-synthesizing enzyme and CD38 that produce NAADP and cADPR, respectively.     

Canonical Wnt signaling skews TGF-β signaling in chondrocytes towards signaling via ALK1 and Smad 1/5/8

BackgroundBoth Wnt signaling and TGF-β signaling have been implicated in the regulation of the phenotype of many cell types including chondrocytes, the only cell type present in the articular cartilage. A changed chondrocyte phenotype, resulting in chondrocyte hypertrophy, is one of the main hallmarks of osteoarthritis. TGF-β signaling via activin-like kinase (ALK)5, resulting in Smad 2/3 phosphorylation, inhibits chondrocyte hypertrophy. In contrast, TGF-β signaling via ALK1, leading to Smad 1/5/8 phosphorylation, has been shown to induce chondrocyte hypertrophy. In this study, we investigated the capability of Wnt3a and WISP1, a protein downstream in canonical Wnt signaling, to skew TGF-β signaling in chondrocytes from the protective Smad 2/3 towards the Smad 1/5/8 pathway.ResultsStimulation with Wnt3a, either alone or in combination with its downstream protein WISP1, decreased TGF-β-induced C-terminal phosphorylation of Smad 2/3. In addition, both Wnt3a and WISP1 increased Smad 1/5/8 phosphorylation at the C-terminal domain in both murine and human chondrocytes. DKK-1, a selective inhibitor of canonical Wnt signaling, abolished these effects. TGF-β signaling via Smad 2/3, measured by the functional CAGA₁₂-Luc reporter construct activity, was decreased by stimulation with Wnt3a in accordance with the decrease in Smad 2/3 phosphorylation found on Western blot. Furthermore, in vivo overexpression of the canonical Wnt8a decreased Smad 2/3 phosphorylation and increased Smad 1/5/8 phosphorylation.ConclusionsOur data show that canonical Wnt signaling is able to skew TGF-β signaling towards dominant signaling via the ALK1/Smad 1/5/8 pathway, which reportedly leads to chondrocyte hypertrophy. In this way canonical Wnts and WISP1, which we found to be increased during experimental osteoarthritis, may contribute to osteoarthritis pathology.     

Regulation of Ca2+/calmodulin-dependent protein kinase kinase β by cAMP signaling

BackgroundCa²⁺/calmodulin-dependent protein kinase kinase (CaMKK) is a pivotal activator of CaMKI, CaMKIV and 5’-AMP-activated protein kinase (AMPK), controlling Ca²⁺-dependent intracellular signaling including various neuronal, metabolic and pathophysiological responses. Recently, we demonstrated that CaMKKβ is feedback phosphorylated at Thr144 by the downstream AMPK, resulting in the conversion of CaMKKβ into Ca²⁺/CaM-dependent enzyme. However, the regulatory phosphorylation of CaMKKβ at Thr144 in intact cells and in vivo remains unclear.MethodsAnti-phosphoThr144 antibody was used to characterize the site-specific phosphorylation of CaMKKβ in immunoprecipitated samples from mouse cerebellum and in transfected mammalian cells that were treated with various agonists and protein kinase inhibitors. CaMKK activity assay and LC-MS/MS analysis were used for biochemical characterization of phosphorylated CaMKKβ.ResultsOur data suggest that the phosphorylation of Thr144 in CaMKKβ is rapidly induced by cAMP/cAMP-dependent protein kinase (PKA) signaling in CaMKKβ-transfected HeLa cells, that is physiologically relevant in mouse cerebellum. We confirmed that the catalytic subunit of PKA was capable of directly phosphorylating CaMKKβ at Thr144 in vitro and in transfected cells. In addition, the basal phosphorylation of CaMKKβ at Thr144 in transfected HeLa cells was suppressed by AMPK inhibitor (compound C). PKA-catalyzed phosphorylation reduced the autonomous activity of CaMKKβ in vitro without significant effect on the Ca²⁺/CaM-dependent activity, resulting in the conversion of CaMKKβ into Ca²⁺/CaM-dependent enzyme.ConclusioncAMP/PKA signaling may confer Ca²⁺-dependency to the CaMKKβ-mediated signaling pathway through direct phosphorylation of Thr144 in intact cells.General significanceOur results suggest a novel cross-talk between cAMP/PKA and Ca²⁺/CaM/CaMKKβ signaling through regulatory phosphorylation.     

Tyrosine kinase but not phospholipid/Ca2+ signaling pathway is involved in interferon-γ stimulation of I-a expression in macrophages

The specific signal transduction pathway(s) involved in the induction of the expression of the MHC class II molecule, la, on macrophages by interferon-γ (IFN-γ) is unclear. In this paper, we assessed the role of several signal transduction pathways including calcium mobilization, phospholipase C, protein kinase C and cyclic nucleotide-dependent protein kinase, and the tyrosine kinase pathways. IFN-γ was unable to mobilize intracellular calcium, unlike platelet-activating factor, which stimulated a threefold increase in cytosolic Ca²⁺ concentration in macrophages. Inhibition of the phospholipase C pathway by U73122 or ET-180CH₃ and of phosphatidic acid phosphohydrolase by propranolol did not suppress IFN-γ-induced la expression. In addition, inhibition of protein kinase C by calphostin C or cyclic nucleotide-dependent protein kinase by HA1004 did not suppress la expression. However, IFN-γ-induced la expression was significantly suppressed when the tyrosine kinase pathway was inhibited with herbimycin A and genestein. In addition, those two inhibitors suppressed tyrosine phosphorylation of several proteins in macrophages that may or may not be involved in the induction of la expression. Thus, IFN-γ used only the tyrosine kinase signaling pathway, but not the phospholipid/Ca²⁺ signaling pathways, to induce la expression in macrophages. © 1996 Wiley-Liss, Inc.     

A key role for KCl cotransport in cell volume regulation in human erythroleukemia cells

AimsKCl cotransport is believed to be involved in volume regulation in various erythroid cells of vertebrates, although the mechanism of activation and the role of the signaling elements involved remain uncertain. In this study, we characterized KCl cotransport activated by hypo-osmotic stress, and clarified several signaling elements involved in the regulation of this pathway within the human erythroleukemia cell line K562.Main methodsThe Cl^?-dependent K⁺ efflux (measured using ⁸⁶Rb⁺) and regulatory volume decrease (RVD) from pre-loaded K562 cells subjected to hypo-osmotic challenge were measured in cells treated with/without KCl cotransport inhibitors [(dihydroindenyl)oxy]alkanoic acid (DIOA) and Ba²⁺. This Cl^?-dependent K⁺ efflux has also been measured in cells treated with the phorbol 12-myristate 13-acetate (protein kinase C (PKC) activator), RO 31-8220 or calphostin C (PKC inhibitor), genistein (protein tyrosine kinase (PTK) inhibitor), PP2 (Src kinase inhibitor), AG18 or AG1478 (epidermal growth factor receptor (EGFR) kinase inhibitor), wortmannin or LY294002 (phosphatatidylinositol 3-kinase (PI 3-kinase) inhibitor), or PD98059 (mitogen-activated protein (MAP) kinase inhibitor).Key findingsCl^?-dependent K⁺ efflux was strongly stimulated by hypo-osmotic challenge and this increased K⁺ efflux was mediated by the DIOA- and Ba²⁺-sensitive KCl cotransport. RO 31-8220, calphostin C, genistein, PP2, AG18, AG1478, wortmannin, LY294002 and PD98059 were shown to significantly inhibit or stimulate the activity of this pathway.SignificanceOur results suggest that the hypo-osmotically-activated KCl cotransport is an important regulator of K562 cell volume, and the activity of this pathway is modulated by PKC, PTK, PI 3-kinase and/or MAP kinases.     

The combined inhibition of the CaMKIIδ and calcineurin signaling cascade attenuates IGF-IIR-induced cardiac hypertrophy

Cardiac hypertrophy is a common phenomenon observed in progressive heart disease associated with heart failure. Insulin-like growth factor receptor II (IGF-IIR) has been much implicated in myocardial hypertrophy. Our previous studies have found that increased activities of signaling mediators, such as calcium/calmodulin-dependent protein kinase II (CaMKII) and calcineurin induces pathological hypertrophy. Given the critical roles played by CaMKII and calcineurin signaling in the progression of maladaptive hypertrophy, we anticipated that inhibition of CaMKII and calcineurin signaling may attenuate IGF-IIR-induced cardiac hypertrophy. The current study, therefore, investigated the effects of IGF-IIR activation on the CaMKII and calcineurin signaling and whether the combinatorial inhibition of the CaMKIIδ and calcineurin signaling could ameliorate IGF-IIR-induced pathological hypertrophy. In the present study, we induced IGF-IIR through the cardiomyocyte-specific transduction of IGFII^Y27L via adeno-associated virus 2 (AAV2) to evaluate its effects on cardiac hypertrophy. Interestingly, it was observed that the activation of IGF-IIR signaling through IGFII^Y27L induces significant hypertrophy of the myocardium and increased cardiac apoptosis and fibrosis. Moreover, we found that Leu²⁷IGF-II significantly induced calcineurin and CaMKII expression. Furthermore and importantly, the combinatorial treatment with CaMKII and calcineurin inhibitors significantly alleviates IGF-IIR-induced hypertrophic responses. Thus, it could be envisaged that the inhibition of IGF-IIR may serve as a promising candidate for attenuating maladaptive hypertrophy. Both calcineurin and CaMKII could be valuable targets for developing treatment strategies against hypertension-induced cardiomyopathies.     

Role of calcineurin in Porphyromonas gingivalis-induced myocardial cell hypertrophy and apoptosis

Summary Background and objective Periodontal pathogen Porphyromonas gingivalis (P. gingivalis) increased cardiomyocyte hypertrophy and apoptosis whereas Actinobaeillus actinomycetemcomitans and Prevotella intermedia had no effects. The purpose of this study is to clarify the role of calcineurin signaling pathway in P.␣gingivalis-induced H9c2 myocardial cell hypertrophy and apoptosis. Methods DNA fragmentation, nuclear condensation, cellular morphology, calcineurin protein, Bcl2-associated death promoter (Bad) and nuclear factor of activated T cell (NFAT)-3 protein products in cultured H9c2 myocardial cell were measured by agarose gel electrophoresis, DAPI, immunofluorescence, and Western blotting following P.␣gingivalis and/or pre-administration of CsA (calcineurin inhibitors cyclosporin A). Results P. gingivalis not only increased calcineurin protein, NFAT-3 protein products and cellular hypertrophy, but also increased DNA fragmentation, nuclear condensation and Bad protein products in H9c2 cells. The increased cellular sizes, DNA fragmentation, nuclear condensation, and Bad of H9c2 cells treated with P. gingivalis were all significantly reduced after pre-administration of CsA. Conclusion Our findings suggest that the activity of calcineurin signal pathway may be initiated by P. gingivalis and further lead to cell hypertrophy and death in culture H9c2 myocardial cells. Supported by the National Science Council, Taiwan     

Resistance training-induced muscle hypertrophy is mediated by TGF-β1-Smad signaling pathway in male Wistar rats

The TGF-β1-Smad pathway is a well-known negative regulator of muscle growth; however, its potential role in resistance training-induced muscle hypertrophy is not clear. The present study proposed to determine whether and how this pathway may be involved in resistance training-induced muscle hypertrophy. Skeletal muscle samples were collected from the control, trained (RT), control + SB431542 (CI_TGF), and trained + SB431542 (RTI_TGF) animals following 3, 5, and 8 weeks of resistance training. Inhibition of the TGF-β1-Smad pathway by SB431542 augmented muscle satellite cells activation, upregulated Akt/mTOR/S6K1 pathway, and attenuated FOXO1 and FOXO3a expression in the CI_TGF group (all p < .01), thereby causing significant muscle hypertrophy in animals from the CI_TGF. Resistance training significantly decreased muscle TGF-β1 expression and Smad3 (P-Smad3^S423/425) phosphorylation at COOH-terminal residues, augmented Smad2 (P-Smad2-L^S245/250/255) and Smad3 (P-Smad3-L^Ser208) phosphorylation levels at linker sites (all p < .01), and led to a muscle hypertrophy which was unaffected by SB431542, suggesting that the TGF-β1-Smad signaling pathway is involved in resistance training-induced muscle hypertrophy. The effects of inhibiting the TGF-β1-Smad signaling pathway were not additive to the resistance training effects on FOXO1 and FOXO3a expression, muscle satellite cells activation, and the Akt/mTOR/S6K1 pathway. Resistance training effect of satellite cell differentiation was independent of the TGF-β1-Smad signaling pathway. These results suggested that the effect of the TGF-β1-Smad signaling pathway on resistance training-induced muscle hypertrophy can be attributed mainly to its diminished inhibitory effects on satellite cell activation and protein synthesis. Suppressed P-Smad3^S423/425 and enhanced P-Smad2-L^S245/250/255 and P-Smad3-L^Ser208 are the molecular mechanisms that link the TGF-β1-Smad signaling pathway to resistance training-induced muscle hypertrophy.     

Cardiac-specific Traf2 overexpression enhances cardiac hypertrophy through activating AKT/GSK3β signaling

Tumor necrosis factor superfamily ligands provoke a dilated cardiac phenotype signal through a common scaffolding protein termed tumor necrosis factor receptor-associated factor 2 (Traf2); however, Traf2 signaling in the adult mammalian cardiac hypertrophy is not fully understood. This study was aimed to identify the effect of Traf2 on cardiac hypertrophy and the underlying mechanisms. A significant up-regulation of Traf2 expression was observed in mice failing hearts. To further investigate the role of Traf2 in cardiac hypertrophy, we used cultured neonatal rat cardiomyocytes with gain and loss of Traf2 function and cardiac-specific Traf2-overexpressing transgenic (TG) mice. In cultured cardiomyocytes, Traf2 positively regulated angiotensin II (Ang II)-mediated hypertrophic growth, as detected by [³H]-Leucine incorporation, cardiac myocyte area, and hypertrophic marker protein levels. Cardiac hypertrophy in vivo was produced by constriction of transverse aortic (TAC) in TG mice and their wild-type controls. The extent of cardiac hypertrophy was evaluated by echocardiography as well as by pathological and molecular analyses of heart samples. Traf2 overexpression in the heart remarkably enhanced cardiac hypertrophy, left ventricular dysfunction in mice in response to TAC. Further analysis of the signaling pathway in vitro and in vivo suggested that these adverse effects of Traf2 were associated with the activation of AKT/glycogen synthase kinase 3β (GSK3β). The present study demonstrates that Traf2 serves as a novel mediator that enhanced cardiac hypertrophy by activating AKT/GSK3β signaling.